Hashimoto's Thyroiditis and Type 1 Diabetes: The Autoimmune Cluster

About 20–30% of adults with type 1 diabetes also carry thyroid antibodies, and a meaningful share progress to overt hypothyroidism. The American Diabetes Association recommends TSH at T1D diagnosis and annually thereafter, with TPO antibodies at least once. Both conditions are treated in parallel — insulin for diabetes, levothyroxine for hypothyroidism.

Why these two diseases travel together

Hashimoto's and type 1 diabetes are not the same disease, but they share the same playbook. Both are organ-specific autoimmune conditions in which T cells and autoantibodies destroy hormone-producing tissue — thyroid follicular cells in Hashimoto's, pancreatic beta cells in T1D [C2][C3]. The susceptibility genes overlap heavily, especially the HLA-DR3 and HLA-DR4 haplotypes that confer risk for both diseases [C4]. PTPN22, CTLA-4, and other immune-regulation loci also contribute to both [C4].

The clinical consequence is that when a patient develops one of these conditions, the lifetime risk of the other rises substantially. The pattern is so consistent that endocrinologists have a name for it: autoimmune polyglandular syndrome type III (APS-III), defined as Hashimoto's or Graves' disease plus another autoimmune disorder other than Addison's [C4][C5]. When Addison's disease is added, the pattern becomes APS-II [C5].

How often it actually happens

Across published series, roughly 20–30% of adults with T1D have detectable thyroid peroxidase (TPO) or thyroglobulin antibodies, and about 5–10% have overt thyroid dysfunction at some point [C4]. The numbers are higher in women and rise with age. Conversely, patients with Hashimoto's have a several-fold higher prevalence of T1D than the general population [C2][C3][C4].

This is why the American Diabetes Association recommends screening every adult with T1D: TSH at diagnosis, TPO antibodies once, and TSH repeated annually (or sooner if symptomatic) [C1][C7]. Pediatric guidelines from ISPAD and ADA are similar.

Screening: what to ask for

For someone with established T1D, a reasonable thyroid workup is [C1][C3][C7]:

• TSH — the primary screening test, repeated annually or with symptoms.
• Free T4 — if TSH is abnormal or borderline.
• TPO antibodies once — if positive, the patient is at higher risk of progression and warrants closer follow-up; if negative, repeat is usually unnecessary unless clinical suspicion changes.
• Thyroglobulin antibodies — adds modest sensitivity; often included in the antibody panel.

For someone with established Hashimoto's, the reverse screening is also reasonable: fasting glucose, HbA1c, and — in young or symptomatic patients — GAD/IA-2/insulin autoantibodies if T1D is suspected [C4]. The autoimmune cluster also justifies celiac screening (tissue transglutaminase IgA with total IgA) [C6] and, if there are unexplained electrolyte disturbances, fatigue, hyperpigmentation, or postural symptoms, Addison screening with morning cortisol or ACTH stimulation [C5].

What to watch for clinically

When both diseases coexist, two presentations cause repeated trouble:

• Unexplained hypoglycemia in untreated or under-treated hypothyroidism. Low thyroid hormone slows the metabolic rate, slows hepatic glucose production, and reduces the counter-regulatory response to insulin [C1][C2]. A patient with stable insulin requirements who suddenly starts having morning lows often has developing hypothyroidism, weight loss from another cause, or both [C2].
• Insulin requirements drift after starting levothyroxine. As metabolic rate normalizes, insulin sensitivity shifts — usually requiring a modest dose increase over weeks to months [C1][C2]. The change is rarely large but warrants closer glucose monitoring during titration.

Weight changes are ambiguous in this population. Hypothyroidism causes some weight gain (usually 2–5 kg from water and reduced metabolism), but well-treated T1D in a young adult often runs lean. The symptom overlap is real and is one reason TSH should be checked rather than assumed [C7].

Levothyroxine and insulin timing

Levothyroxine is taken on an empty stomach, 30–60 minutes before food, with water [C1][C7]. Insulin timing follows the meal, not the levothyroxine, so the two regimens don't directly collide — but a few practical points matter:

• Don't take levothyroxine with the calcium, iron, or multivitamin many T1D patients use. Separate by at least 4 hours [C1].
• Don't co-administer with PPI or H2 blocker doses — they raise gastric pH and can drop absorption [C1].
• Recheck TSH 6–8 weeks after any dose change — and after that, glucose patterns may shift slightly with the new thyroid state [C1].
• Tell the endocrinologist what your insulin-to-carb ratio is doing. Stable basal/bolus numbers help confirm the levothyroxine dose is correct [C2].

See our levothyroxine-empty-stomach article for the absorption details.

Pregnancy and fertility planning

For women with both T1D and Hashimoto's planning pregnancy, preconception thyroid optimization is non-negotiable. The targets are tighter than in non-pregnant adults: TSH under 2.5 mIU/L before conception, and most experts target under 2.5 mIU/L throughout the first trimester [C1][C7]. Levothyroxine requirements typically rise 20–30% in pregnancy, so dose increases are expected. T1D management in pregnancy is its own subject, but the two conditions interact: hypothyroidism that is under-treated in early pregnancy worsens outcomes that T1D already pressures (miscarriage, preterm birth, neurodevelopmental measures) [C1].

What does NOT help

• Avoiding gluten without a celiac diagnosis — popular in the autoimmune community, but a strict gluten-free diet in someone without celiac doesn't improve thyroid antibodies or T1D control in the evidence base [C6]. Screen for celiac and treat the result; don't restrict empirically. See gluten-free-hashimotos.
• Mega-dose vitamins and "autoimmune protocol" diets without indication. Vitamin D repletion is reasonable if deficient; megadosing vitamin A, iodine, or selenium is not [C3][C4].
• Stopping levothyroxine to "let the body heal." Both Hashimoto's hypothyroidism and T1D are chronic; replacement is the treatment, not the problem [C1][C7].
• Bovine thyroid glandulars marketed as autoimmune-friendly. The American Thyroid Association recommends levothyroxine as first-line; glandulars have inconsistent T3/T4 content and add no benefit in autoimmune disease [C1][C7].

Practical guidelines

1. Get a TSH at every annual T1D visit, and a TPO antibody at least once [C1][C7].
2. Get a celiac screen at least once (tTG-IgA + total IgA) and again if GI symptoms develop [C6].
3. Be alert for Addison's: unexplained hypoglycemia plus hyperpigmentation, salt craving, postural lightheadedness, or hyponatremia warrants a morning cortisol [C5].
4. Share-care matters. Make sure your endocrinologist (or PCP coordinating both) sees the full picture — insulin doses, levothyroxine doses, glucose patterns, TSH trend.
5. Recheck TSH 6–8 weeks after any levothyroxine dose change, and monitor glucose patterns more closely for a few weeks afterward [C1].
6. Don't substitute one therapy for the other. Insulin treats T1D. Levothyroxine treats hypothyroidism. They run in parallel [C1][C7].

Frequently asked questions

If I have T1D, how often should I get my thyroid checked? ADA-aligned guidance: TSH at T1D diagnosis, TPO antibodies once, and TSH annually (or sooner with symptoms) [C1][C7].

Will levothyroxine change my insulin needs? Often modestly, yes. Hypothyroidism slows metabolism and reduces insulin requirements; as thyroid hormone normalizes, insulin needs typically rise slightly [C1][C2]. Watch your glucose patterns for several weeks after a dose change.

Should everyone with Hashimoto's get screened for T1D? Not routinely. ADA does not recommend autoantibody screening in asymptomatic adults with Hashimoto's. Screen with fasting glucose and HbA1c, and add GAD/IA-2 antibodies only if there's clinical suspicion of T1D (rapid weight loss, ketosis, lean phenotype with hyperglycemia) [C4].

Do I need to go gluten-free if I have Hashimoto's and T1D? Only if celiac disease is confirmed. About 5–10% of people with T1D have celiac; screen with tTG-IgA + total IgA. A strict gluten-free diet without celiac doesn't improve thyroid or diabetes outcomes [C6]. See gluten-free-hashimotos.

What is APS-III versus APS-II? APS-III is Hashimoto's or Graves' plus another autoimmune disease other than Addison's (most commonly T1D, celiac, vitiligo) [C4]. APS-II adds Addison's to the picture — much less common but clinically important because adrenal crisis is life-threatening [C5].

Bottom line

Hashimoto's and T1D share HLA risk haplotypes and immune-regulation genes, so they co-cluster: roughly a quarter of adults with T1D develop thyroid antibodies and a meaningful share develop overt hypothyroidism over time [C2][C3][C4]. Screen TSH annually in T1D, screen once for TPO antibodies, and add celiac screening because that completes the most common autoimmune cluster [C1][C6][C7]. Treat both conditions in parallel — insulin for diabetes, levothyroxine for hypothyroidism — and monitor glucose patterns around any thyroid dose change [C1][C2]. Stay alert for Addison's, the rarer but most dangerous addition to this cluster [C5].

Sources

1. [C1] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
2. [C2] Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646–2655. PubMed: 12826640
3. [C3] Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391–397. PubMed: 24434360
4. [C4] Heydarzadeh S et al. Endocrine polyautoimmunity: Mechanistic insights and the future of AI-driven diagnostics. 2025. PubMed: 41268326
5. [C5] Yao Z et al. Delayed diagnosis of the full triad autoimmune polyendocrine syndrome type 2 with adrenal crisis: a case report and literature review. 2025. PubMed: 40416965
6. [C6] Murray JA et al. Celiac Disease. 2026. PubMed: 41950475
7. [C7] American Thyroid Association. Hypothyroidism — Patient Information. thyroid.org

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.